Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > There’s not even a vote re salzman purchase that will wipe r

<< Previous

Bullboard Posts

Next >>

Post by edroseon Jun 17, 2020 9:14am

177 Views

Post# 31159281

There’s not even a vote re salzman purchase that will wipe r

Out retail investors with 20:1 rs ,salzman will own 49% of kly Then we must pay salzman 29 million dollars plus 5 million paid in shares. Resulting in salzman owning the vast majority of kly

barda funding zero guarantees

kly doesn't have money to do research on r107 and we can't even finish our phase3 study which would give us product bringing in min 400 million/yr
shy did ceo and board stop dev our product by finding partner

why don't they give us update re 5 million pp. how much money did they raise

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale